Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone methyl in ESRD and T2DM patients on peritoneal dialysis
NCT01576887Phase 2Withdrawn
- Sponsor
- Biogen
- Start
- Jul 2012
- Primary completion
- Oct 2012
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of bardoxolone methyl in end stage renal disease (ESRD), sponsored by Biogen. Planned start Jul 2012; status: withdrawn.
02
Drugs
bardoxolone methyl
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01576887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576887.